Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

1. Pérez-Lamas, L.
2. de Paz Arias, R.
3. Díaz, R.M.A.
4. Montero, L.F.C.
5. Payer, Á.R.
6. Sierra, M.
7. Marín, F.F.
8. López, R.P.
9. Cirici, B.X.
10. Steegmann, J.L.
11. Gómez Casares, M.T.
12. Martínez-López, J.
13. García-Gutiérrez, V.